<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917150</url>
  </required_header>
  <id_info>
    <org_study_id>197-08-801</org_study_id>
    <secondary_id>JapicCTI-090770</secondary_id>
    <nct_id>NCT00917150</nct_id>
  </id_info>
  <brief_title>To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Dose-comparison Trial of OPC-6535 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of OPC-6535 in COPD patients, using the measurement of&#xD;
      trough FEV1 over time as the primary endpoint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Measurement over time (from baseline over the 24-month treatment period) and change from baseline to end of the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 24 Months in Total Symptom Diary Score</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Subjects were required to keep a symptom diary throughout the entire trial period from the start of investigational medicinal product (IMP) administration in the washout period until the end of the treatment period. Assessment items included scores for shortness of breath, cough, and sputum, IMP compliance, use of salbutamol and respiratory symptom medications, and smoking status. Subjects recorded a score of between 0 and 3, with 0 indicating no symptoms and 3 indicating a high level of symptoms, for each domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 24 Months in St. George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>The SGRQ is a self-administered questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being in three domains: symptoms, activity, and impact on daily life. The SGRQ was completed by each subject prior to IMP administration at baseline and at Month 6, Month 12, Month 18, and Month 24 (end of treatment).&#xD;
A weighted score based on population norms for each dimension and total was evaluated. Scores were expressed as a percentage of overall impairment where 100 represented worst possible health status and 0 indicated best possible health status. Scores were calculated when less than 24% of the item scores were missing, otherwise the scores were set to missing. Where there were multiple answers for a question, the worst case was used.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">771</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>OPC-6535 12.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-6535 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-6535 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetomilast (OPC-6535)</intervention_name>
    <description>oral administration of 12.5mg OPC-6535, once daily for 24months</description>
    <arm_group_label>OPC-6535 12.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetomilast (OPC-6535)</intervention_name>
    <description>oral administration of 25mg OPC-6535, once daily for 24months</description>
    <arm_group_label>OPC-6535 25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetomilast (OPC-6535)</intervention_name>
    <description>oral administration of 50 mg OPC-6535, once daily for 24months</description>
    <arm_group_label>OPC-6535 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration of placebo, once daily for 24months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40 to 75 years, inclusive, at the time informed consent is obtained&#xD;
&#xD;
          -  Ability to provide own written informed consent&#xD;
&#xD;
          -  Agree to use an appropriate method of contraception until 3 months after the last dose&#xD;
             of the investigational medicinal product (IMP)&#xD;
&#xD;
          -  A rating of 1 or higher on the Goddard scale in assessment of emphysema severity by&#xD;
             chest CT scan at screening&#xD;
&#xD;
          -  Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) of&#xD;
             less than 70% at screening&#xD;
&#xD;
          -  Cigarette smoking history of at least 20 pack years at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with obstructive disorders due to bronchial asthma&#xD;
&#xD;
          -  Subjects receiving long-term oxygen therapy&#xD;
&#xD;
          -  Subjects with active tuberculosis or obvious bronchiectasis&#xD;
&#xD;
          -  Complication of malignant tumor&#xD;
&#xD;
          -  Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders&#xD;
&#xD;
          -  Uncontrolled condition with COPD exacerbation of level 2 or 3 within 8 weeks prior to&#xD;
             the start of washout period (within 12 weeks prior to start of treatment period)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Central China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northeast China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northwest China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southwest China Area</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region, Et Al.</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul, Et Al.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <results_first_submitted>March 11, 2021</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic obstructive pulmonary disease</keyword>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OPC-6535 12.5 mg</title>
          <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="P2">
          <title>OPC-6535 25 mg</title>
          <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="P3">
          <title>OPC-6535 50 mg</title>
          <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Oral administration of placebo once daily for 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="198"/>
                <participants group_id="P3" count="191"/>
                <participants group_id="P4" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="149"/>
                <participants group_id="P4" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population consisted all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
      <group_list>
        <group group_id="B1">
          <title>OPC-6535 12.5 mg</title>
          <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="B2">
          <title>OPC-6535 25 mg</title>
          <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="B3">
          <title>OPC-6535 50 mg</title>
          <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Oral administration of placebo once daily for 24 months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="192"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="191"/>
            <count group_id="B4" value="190"/>
            <count group_id="B5" value="771"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="7.63"/>
                    <measurement group_id="B2" value="64.0" spread="7.01"/>
                    <measurement group_id="B3" value="63.2" spread="7.55"/>
                    <measurement group_id="B4" value="63.4" spread="7.24"/>
                    <measurement group_id="B5" value="63.2" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="148"/>
                    <measurement group_id="B5" value="590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months</title>
        <description>Measurement over time (from baseline over the 24-month treatment period) and change from baseline to end of the treatment period.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-6535 12.5 mg</title>
            <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>OPC-6535 25 mg</title>
            <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O3">
            <title>OPC-6535 50 mg</title>
            <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral administration of placebo once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months</title>
          <description>Measurement over time (from baseline over the 24-month treatment period) and change from baseline to end of the treatment period.</description>
          <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0481"/>
                    <measurement group_id="O2" value="-0.023" spread="0.0481"/>
                    <measurement group_id="O3" value="-0.018" spread="0.0473"/>
                    <measurement group_id="O4" value="-0.035" spread="0.0480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 24 Months in Total Symptom Diary Score</title>
        <description>Subjects were required to keep a symptom diary throughout the entire trial period from the start of investigational medicinal product (IMP) administration in the washout period until the end of the treatment period. Assessment items included scores for shortness of breath, cough, and sputum, IMP compliance, use of salbutamol and respiratory symptom medications, and smoking status. Subjects recorded a score of between 0 and 3, with 0 indicating no symptoms and 3 indicating a high level of symptoms, for each domain.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-6535 12.5 mg</title>
            <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>OPC-6535 25 mg</title>
            <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O3">
            <title>OPC-6535 50 mg</title>
            <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral administration of placebo once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 24 Months in Total Symptom Diary Score</title>
          <description>Subjects were required to keep a symptom diary throughout the entire trial period from the start of investigational medicinal product (IMP) administration in the washout period until the end of the treatment period. Assessment items included scores for shortness of breath, cough, and sputum, IMP compliance, use of salbutamol and respiratory symptom medications, and smoking status. Subjects recorded a score of between 0 and 3, with 0 indicating no symptoms and 3 indicating a high level of symptoms, for each domain.</description>
          <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="161"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063" spread="0.0606"/>
                    <measurement group_id="O2" value="0.073" spread="0.0606"/>
                    <measurement group_id="O3" value="0.077" spread="0.0597"/>
                    <measurement group_id="O4" value="0.101" spread="0.0606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 24 Months in St. George's Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>The SGRQ is a self-administered questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being in three domains: symptoms, activity, and impact on daily life. The SGRQ was completed by each subject prior to IMP administration at baseline and at Month 6, Month 12, Month 18, and Month 24 (end of treatment).&#xD;
A weighted score based on population norms for each dimension and total was evaluated. Scores were expressed as a percentage of overall impairment where 100 represented worst possible health status and 0 indicated best possible health status. Scores were calculated when less than 24% of the item scores were missing, otherwise the scores were set to missing. Where there were multiple answers for a question, the worst case was used.</description>
        <time_frame>Baseline, 24 months</time_frame>
        <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-6535 12.5 mg</title>
            <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O2">
            <title>OPC-6535 25 mg</title>
            <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
          </group>
          <group group_id="O3">
            <title>OPC-6535 50 mg</title>
            <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Oral administration of placebo once daily for 24 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 24 Months in St. George's Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>The SGRQ is a self-administered questionnaire designed to measure and quantify the impact of chronic respiratory disease on health-related quality of life (QOL) and well-being in three domains: symptoms, activity, and impact on daily life. The SGRQ was completed by each subject prior to IMP administration at baseline and at Month 6, Month 12, Month 18, and Month 24 (end of treatment).&#xD;
A weighted score based on population norms for each dimension and total was evaluated. Scores were expressed as a percentage of overall impairment where 100 represented worst possible health status and 0 indicated best possible health status. Scores were calculated when less than 24% of the item scores were missing, otherwise the scores were set to missing. Where there were multiple answers for a question, the worst case was used.</description>
          <population>ITT population consisted of all subjects randomized to double-blind therapy, regardless of any protocol violation.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="3.80"/>
                    <measurement group_id="O2" value="-7.9" spread="3.80"/>
                    <measurement group_id="O3" value="-7.7" spread="3.73"/>
                    <measurement group_id="O4" value="-10.4" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration until follow-up (2 weeks after the end of treatment or early termination)</time_frame>
      <desc>Safety analyses were conducted on the safety population, defined all randomized subjects who took at least one dose of the IMP. A TEAE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the IMP, regardless of judgment of relationship to the IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>OPC-6535 12.5 mg</title>
          <description>Oral administration of 12.5mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="E2">
          <title>OPC-6535 25 mg</title>
          <description>Oral administration of 25mg OPC-6535 once daily for 24 months</description>
        </group>
        <group group_id="E3">
          <title>OPC-6535 50 mg</title>
          <description>Oral administration of 50 mg OPC-6535 once daily for 24 months (started from 25 mg for the first 2 weeks and the dose was titrated to 50 mg from the third week)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Oral administration of placebo once daily for 24 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Ver. 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic granulomatous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gingival cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Computerised tomogram thorax abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Astrocytoma malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Chronic myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Spinal meningeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dyssomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disorder</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Ver. 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., LTD.</organization>
      <phone>+81-3-6361-7366</phone>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

